Moleculin Biotech, Inc. Additional Paid in Capital, Common Stock
Moleculin Biotech, Inc. (MBRX) had Additional Paid in Capital, Common Stock of $238.13 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-13
- 2026-06-30: Additional Paid in Capital, Common Stock $238.13M.
- 2026-03-31: Additional Paid in Capital, Common Stock $234.08M.
- 2025-12-31: Additional Paid in Capital, Common Stock $221.00M.
- 2025-09-30: Additional Paid in Capital, Common Stock $194.63M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $238.13M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $234.08M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $221.00M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $194.63M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $192.58M 10-Q · filed 2025-11-13 | $160.29M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $192.16M 10-Q · filed 2025-11-13 | $159.87M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $183.69M 10-K · filed 2026-03-18 | $159.38M 10-K · filed 2025-03-21 |
| 2024-09-30 | $158.96M 10-Q · filed 2024-11-08 | |
| 2024-06-30 | $158.60M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $158.18M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $157.65M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $156.45M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $155.96M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $155.40M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $153.99M 10-K · filed 2024-03-22 | |
| 2022-09-30 | $153.45M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $152.76M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $152.26M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $151.73M 10-K · filed 2023-03-22 | |
| 2021-09-30 | $151.18M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $150.23M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $149.79M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $74.67M 10-K · filed 2022-03-24 | |
| 2020-09-30 | $68.65M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $66.43M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $56.01M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $55.05M 10-K · filed 2021-03-24 | |
| 2019-09-30 | $54.67M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $53.64M 10-Q · filed 2019-08-16 | |
| 2019-03-31 | $45.02M 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $40.56M 10-K · filed 2020-03-19 | |
| 2018-09-30 | $38.49M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $38.25M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $36.95M 10-Q · filed 2018-05-14 | |
| 2017-12-31 | $31.58M 10-K · filed 2019-02-21 | |
| 2017-09-30 | $29.93M 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $27.71M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $21.13M 10-Q · filed 2017-05-12 | |
| 2016-12-31 | $19.62M 10-K · filed 2018-03-28 | $19.62M 10-K · filed 2017-04-03 |
| 2016-09-30 | $19.49M 10-Q · filed 2016-11-21 | |
| 2016-06-30 | $19.30M 10-Q · filed 2016-11-21 | |
| 2016-03-31 | $388.47K 10-Q · filed 2016-06-16 | |
| 2015-12-31 | $0.00 10-K · filed 2017-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |